Department of Cardiology, Dr. Ersin Arslan Research and Education Hospital, Gaziantep, Turkey.
Department of Physiology, Faculty of Medicine, Hacettepe University, School of Medicine, Sihhiye, Ankara, Turkey.
Cardiovasc Toxicol. 2021 Sep;21(9):747-758. doi: 10.1007/s12012-021-09665-y. Epub 2021 Jun 5.
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against doxorubicin (DOX)-induced acute cardiotoxicity. Non-diabetic Sprague-Dawley rats were randomized into four groups. The control group received serum physiologic (1 ml), the EMPA group received EMPA, the DOX group was administered cumulatively 18 mg/kg body weight DOX. The DOX+EMPA group was administered DOX and EMPA. In the DOX group, LVDED (P < 0.05) and LVSED (P < 0.01), QTc interval (P < 0.001), the ratio of karyolysis and karyorrhexis (P < 0.001) and infiltrative cell proliferation (P < 0.001) were found to be higher than; EF, FS and normal cell morphology were lower than the control group (P < 0.001). In the DOX+EMPA group, LVEDD (P < 0.05) and LVESD (P < 0.01) values, QTc interval (P < 0.001), karyolysis and karyorrhexis ratios (P < 0.001) and infiltrative cell proliferation were lower (P < 0.01); normal cell morphology and EF were higher compared to the DOX group (P < 0.001). Our results showed that empagliflozin significantly ameliorated DOX-induced acute cardiotoxicity.
恩格列净（EMPA）是一种 SGLT-2 抑制剂，对心血管结局有积极影响。本研究旨在评估 EMPA 对阿霉素（DOX）诱导的急性心脏毒性的可能保护作用。非糖尿病 Sprague-Dawley 大鼠随机分为四组。对照组给予生理血清（1ml），EMPA 组给予 EMPA，DOX 组给予累积 18mg/kg 体重 DOX。DOX+EMPA 组给予 DOX 和 EMPA。在 DOX 组中，LVDED（P<0.05）和 LVSED（P<0.01）、QTc 间期（P<0.001）、核溶解和核碎裂的比例（P<0.001）和浸润性细胞增殖（P<0.001）高于对照组；EF、FS 和正常细胞形态低于对照组（P<0.001）。在 DOX+EMPA 组中，LVEDD（P<0.05）和 LVESD（P<0.01）、QTc 间期（P<0.001）、核溶解和核碎裂的比例（P<0.001）和浸润性细胞增殖降低（P<0.01）；正常细胞形态和 EF 高于 DOX 组（P<0.001）。我们的结果表明，恩格列净显著改善了 DOX 诱导的急性心脏毒性。
